Investigating Regional Differences in Cardiovascular Outcomes Among Patients Diagnosed with Hypertrophic Cardiomyopathy

Author(s)

Reza N1, Batra K2, Amos QR2, Anderson AJ2, Buikema A2, Butzner M3, Shreay S4, Owens AT1
1University of Pennsylvania, Philadelphia, CA, USA, 2Optum Life Sciences, Eden Prairie, MN, USA, 3Cytokinetics, Incorporated, South San Francisco, CA, USA, 4Cytokinetics, South San Francisco, CA, USA

OBJECTIVES: Studies examining the associations between geographic region and cardiovascular (CV) outcomes in patients with hypertrophic cardiomyopathy (HCM) were limited in size. We evaluated these associations in a large, national cohort of patients with HCM.

METHODS: Retrospective cohort study of adults diagnosed with HCM in Optum’s medical/ pharmacy claims and electronic health record data (January 2013 to December 2021). We report incidence rates of CV outcomes (atrial fibrillation [AF], stroke, heart failure [HF], ventricular tachycardia [VT], and ventricular fibrillation [VF] from first HCM diagnosis until death, health plan disenrollment, or study end. Kaplan Meier analysis for 3-year all-cause mortality was conducted by region: Midwest (reference group), Northeast, South, and West.

RESULTS: Among 24,586 HCM patients (49% female; 74.0% White; mean age 61.3 ± 14.9 years), 42.7% of patients resided in the Midwest (Northeast 27.1%; South 22.4%; West 7.8%). Northeast patients were less likely to receive beta-blockers, calcium channel blockers, and pacemaker but more likely to receive disopyramide (p<0.001). Patients in the South were less likely to receive beta-blockers (p<0.001) but more likely to receive calcium channel blockers, implantable cardioverter-defibrillators, pacemakers, and septal myectomy (all p<0.05). Patients in the West were less likely to receive beta-blockers but more likely to receive disopyramide (all p<0.01). Patients in the Northeast were less likely to experience AF, stroke, HF, and VF (all p<0.01) and patients in the West were less likely to experience stroke (p=0.020). Patients in the South were more likely to experience AF and HF (p<0.001). All-cause mortality rate was lowest in the Northeast (5.2%; p<0.001), with similar rates in the South (8.5%), West (8.3%), and Midwest (8.0%).

CONCLUSIONS: Incidence of adverse CV outcomes was less frequent in the Northeast and West and all-cause mortality was significantly lower in the Northeast. Further research is required to understand and address these regional differences.

Conference/Value in Health Info

2024-05, ISPOR 2024, Atlanta, GA, USA

Value in Health, Volume 27, Issue 6, S1 (June 2024)

Code

CO72

Topic

Clinical Outcomes, Study Approaches

Topic Subcategory

Clinical Outcomes Assessment, Electronic Medical & Health Records

Disease

Cardiovascular Disorders (including MI, Stroke, Circulatory), Rare & Orphan Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×